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ABSTRACT
Retinal degeneration often results in the loss of light-sensing photoreceptors, which leads to per-
manent vision loss. Generating transplantable retinal photoreceptors using human somatic cell-
derived induced pluripotent stem cells (iPSCs) holds promise to treat a variety of retinal degenera-
tive diseases by replacing the damaged or dysfunctional native photoreceptors with healthy and
functional ones. Establishment of effective methods to produce retinal cells including photorecep-
tors in chemically defined conditions using current Good Manufacturing Practice (cGMP)-manufac-
tured human iPSC lines is critical for advancing cell replacement therapy to the clinic. In this study,
we used a human iPSC line (NCL-1) derived under cGMP-compliant conditions from CD341 cord
blood cells. The cells were differentiated into retinal cells using a small molecule-based retinal
induction protocol. We show that retinal cells including photoreceptors, retinal pigmented epithe-
lial cells and optic cup-like retinal organoids can be generated from the NCL-1 iPSC line. Addition-
ally, we show that following subretinal transplantation into immunodeficient host mouse eyes,
retinal cells successfully integrated into the photoreceptor layer and developed into mature photo-
receptors. This study provides strong evidence that transplantable photoreceptors can be gener-
ated from a cGMP-manufactured human iPSC line for clinical applications. STEM CELLS
TRANSLATIONAL MEDICINE 2018;7:210–219
SIGNIFICANCE STATEMENT
This study describes the generation of retinal cells including photoreceptors, as well as retinal
pigmented epithelial cells from a current Good Manufacturing Practice compliant human
induced pluripotent stem cell (iPSC) line after 12 weeks of directed differentiation using a novel
small-molecule induction protocol. This study provides proof-of-concept that clinically compliant
human iPSC lines can be used for making clinically relevant retinal cell types especially photore-
ceptors, thereby supporting the advancement of cell replacement therapy for preclinical studies
and clinical applications.
INTRODUCTION
Various inherited and acquired retinal degenera-
tive disorders often lead to the loss of photore-
ceptors (rods and cones) in the retina leading to
severe and permanent visual loss. This is due to
the fact that the adult mammalian retina lacks
any significant regenerative potential. In the past
few decades, significant progress has been made
in the understanding of the pathogenesis of a
range of retinal degenerative diseases. However,
currently available treatment options are very lim-
ited and mainly palliative. Cell replacement ther-
apy is a promising therapeutic strategy for retinal
degenerative diseases especially following the
discovery of pluripotent stem cell sources. A num-
ber of research groups have shown the potential
of using either human embryonic stem cells
(hESCs) or induced pluripotent stem cell (iPSCs)
toward generation of various retinal cells [1–6].
ESC or iPSC derived retinal photoreceptors were
tested for their integration potential in either nor-
mal or degenerative retinas of murine models of
retinal degeneration conditions and have shown
various levels of survival, integration and visual
function restoration [4, 7, 8]. Due to the ethical
concerns associated with using hESCs in patients
clinically, iPSCs generated from the somatic cells
of the donors including the patients are consid-
ered a good alternative cellular source. iPSCs have
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ENABLING TECHNOLOGIES FOR CELL-BASED CLINICAL
TRANSLATION
a number of advantages including the ability to generate banks
from super donor pools which match large population groups [9],
as well the eventual future use of patient’s own cells to generate
matched differentiated cells [10]. There are some drawbacks to
iPSCs for cell therapy including the use of oncogenes in their gen-
eration as well as incorporation of mutations during the process
of generation of these lines [11, 12] though some of these con-
cerns also exist for hESC lines in culture [13]. Thus, clinically-
compliant iPSCs may require thorough validation prior to clinical
use. Recent advancements in pluripotent stem cell technology
have shown the success of generating integration-free iPSC lines
using either episomal plasmids, Sendai virus-based vectors or pig-
gyBac transposons which are safer for clinical applications [14–19]
There is an urgent demand for a bank of iPSC lines produced
under current Good Manufacturing Practice (cGMP) conditions to
forward the stem cell research toward clinical translation. As of
today, there are several cGMP-compatible iPSC lines reported and
few of them are available for evaluation [20, 21]. In this study, we
used a clinically compliant iPSC line (NCL1) to make retinal photo-
receptors using our small molecule-based retinal induction proto-
col. NCL1 line was developed under cGMP-compliant condition
including tissue sourcing, manufacturing, testing and storage. The
line was generated from isolated cord blood-derived CD341 cells
which were reprogrammed using episomal plasmids in feeder-
free culture condition [20]. The iPSCs meet the requirement of
clinical application and can be used for differentiation into clini-
cally relevant cells, holding potential for clinical applications.
In this study, we describe the generation of retinal cells includ-
ing photoreceptors, as well as retinal pigmented epithelial (RPE)
cells from NCL1 line after 12 weeks of directed differentiation
using a novel small-molecule induction protocol. The protocol also
allowed for generation of three-dimensional (3D) retinal organoids
in low-attachment culture conditions. Upon subretinal transplan-
tation of mono-layer cultured cells, the iPSC-derived retinal cells
were able to integrate into immunodeficient host mouse retina at
8 weeks post transplantation and displayed mature photoreceptor
morphology and expressed markers specific for mature functional
photoreceptors. This study provides proof-of-concept that clini-
cally compliant human iPSC lines can be used for making clinically
relevant retinal cell types especially photoreceptors, thereby sup-
porting the advancement of cell replacement therapy for preclini-
cal studies and clinical applications.
MATERIALS AND METHODS
iPSC Culture and Retinal Induction
The NCL1 line was obtained from NxCell Inc (Novato, CA). The cells
were maintained in Essential 8 basal medium (ThermoFischer Sci-
entific, Waltham, MA) supplemented with 1% Essential 8 supple-
ment (ThermoFischer Scientific, Waltham, MA) and 1% Penicillin
Streptomycin Amphotericin B (Lonza, Walkersville, MD). Cells
were grown onMatrigel-coated (BD Biosciences, San Jose, CA) cul-
ture plates in a 378C incubator with 5% CO2 and 5% O2. Retinal
differentiation was induced in iPSCs in medium that contains Dul-
becco’s modified Eagle medium (DMEM)/F-12 1:1 (GE Healthcare
Life Sciences, Marlborough, MA) with 10% Knockout Serum
Replacement (KSR, ThermoFischer Scientific), 1% Penicillin Strep-
tomycin Amphotericin B, 1% Sodium Pyruvate (ThermoFischer
Scientific), 1% Sodium Bicarbonate (ThermoFischer Scientific), 1%
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) Buffer
(ThermoFischer Scientific), 1% MEM (Minimum Essential
Medium) Nonessential Amino Acids (ThermoFischer Scientific),
and 1% N1 Media Supplement (Sigma-Aldrich, St. Louis, MO). Two
retinal induction protocols were used to compare relative effi-
ciency of retinal induction. One protocol contains 10 ng/ml of
human recombinant protein Dickkopf-1 (DKK1) (R&D Systems,
Minneapolis, MN, https://www.rndsystems.com), 10 ng/ml of
human recombinant Noggin (R&D Systems), and 10 ng/ml of
human recombinant Insulin-like growth factor 1 (IGF1) (R&D Sys-
tems) (referred as DIN) as reported previously [7, 22]. The new
small molecule induction protocol contains 2 mM of IWR1 (Sigma-
Aldrich), 10 mM of SB431542 (Stemgent, Lexington, MA, https://
www.stemgent.com), 100 nM of LDN193189 (Stemgent), and 10
ng/ml of human recombinant IGF1 (R&D Systems) (referred as
ISLI). The two protocols were used to treat undifferentiated iPSCs
in parallel for 5 to 7 days with daily medium change. Cells were
then dissociated and passaged onto 6-well Matrigel-coated plates
at a passaging ratio of 1:3 in Neural Stem Cell (NSC) medium that
was comprised of DMEM/F-12 1:1 (GE Healthcare Life Sciences),
0.5% Fetal Bovine Serum (FBS, Atlanta Biologicals, Atlanta Biologi-
cals, Flowery Branch, GA, https://www.atlanta-biologicals.com),
1% Penicillin Streptomycin Amphotericin B , 1% Sodium Pyruvate,
1% Sodium Bicarbonate, 1% HEPES Buffer, 1% MEM Non-Essential
Amino Acids, and 1% of N1 media supplement. The neuro-retinal
regions were manually separated from co-existing RPE cells, disso-
ciated and cultured in Matrigel-coated 6-well plates as monolayer.
The neural cells were maintained in NSC media and serially pas-
saged using Accutase (Global Cell Solutions, North Garden, VA) at
1:3 ratio upon confluency. Some neuro-retinal regions were also
picked and cultured in low-attachment culture plates to allow for-
mation of retinal organoids. The remaining RPE cells were cultured
in RPE medium that contains Minimal Essential Medium with Ear-
le’s Balanced salt solution (MEM/EBSS) (GE Healthcare Life Scien-
ces) with 1% FBS, 1% Penicillin Streptomycin Amphotericin B, 1%
Glutamax (ThermoFischer Scientific), 0.25 mg/ml Taurine (Sigma-
Aldrich), 10 mg/ml Hydrocortisone (Sigma-Aldrich), and 0.0065
mg/ml Triiodo-Thyronine (Sigma-Aldrich), and 1% N1 media sup-
plement indefinitely till the time of analysis.
Culture of 3D Retinal Organoids
Two to four weeks of retinal induction rosette-like neuronal clus-
ters started to form in culture. The clusters were manually isolated
and cultured in ultra-low attachment 6-well plates (ThermoFischer
Scientific) in NSC medium to allow self-organization and differen-
tiation. NSC medium was changed 2 to 3 times per week till the
time of analysis.
Animal Care
The IL2rg–/– mice (B6.129S4-Il2rgtm1Wjl/J) were purchased from
Jackson Laboratories. All mice used in this study were housed and
bred at the Association for Assessment and Accreditation of Labo-
ratory Animal Care International (AAALAC) accredited vivarium of
The Buck Institute for Research on Aging in a Specific Pathogen
Free facility and housed in individually ventilated cages on a
standard 12:12 light cycle. All procedures were approved by the
Buck Institute Institutional Animal Care and Use Committee
(IACUC) and performed in accordance with the guidelines and
regulations set forth by the committee.
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Transplantation of Human iPSC-Derived Retinal Cells
Human iPSC-derived retinal cells were treated with fresh NSC
medium with 1 mM Thiazovivin (Selleck Chemicals, Houston, TX) 1
hour prior to dissociation. The cells were then dissociated with
Accutase. The final cell suspension was prepared in NSC medium
containing 500,000 cells per microliter. The cell suspension was
kept on ice until transplantation.
Transplantation procedure is based on previously
described technique [23]. Animals were anesthetized for 15
minutes with 2% Isoflurane inhalation. Pupils were dilated
using a mixture of 5% Phenylephrine (Arcos Organics, Geel,
Belgium) and 1% Tropicamide (Alfa Aesar, Ward Hill, MA) and
anesthetized with topical 0.5% Proparacaine hydrochloride
ophthalmic solution (Akorn, Vernon Hills, IL). Following testing
the depth of anesthesia, a small hole was made on the periph-
eral cornea using a 30G needle visualized using a dissecting
microscope (Olympus, San Jose, CA). A pulled graduated glass
pipet (Wiretrol II, 5-0000-2005, Drummond Scientific Com-
pany, Broomall, PA) containing 1–1.5 ll of cell suspension
(500,000–750,000 cells) was inserted into the anterior cham-
ber of the eye through the hole, advanced gently across the
iris until it reached the subretinal space of the eye. The cells
were then slowly injected into the subretinal space. The pipet
was withdrawn slowly to minimize backflow of cell suspension.
The Neomycin and Polymyxin B sulfates and Bacitracin Zinc
Ophthalmic Ointment (Akorn) was applied to the eye and mice
were monitored for full recovery and general health until
euthanasia.
Immunocytochemistry and Immunohistochemistry
Retinal cells, RPE cells, retinal organoids, and transplanted eyes
were collected and fixed with 4% Paraformaldehyde for 30 minutes
to 2 hours at room temperature followed by thorough wash in 1X
Phosphate-Buffered Saline (PBS) buffer. The retinal organoids and
eye samples were embedded with embedding medium that con-
tains 7.5% gelatin (Sigma) and 15% sucrose (Sigma) in 1X PBS
buffer. Cryo-embedded eye samples were sectioned to 14 lm
thickness. Fixed cells, retinal organoids, and eye sections were ana-
lyzed with the antibodies listed in Supporting Information Table S1.
Secondary antibody staining was done using the corresponding
Alexa 488, 555, 594, 647 fluorescent-tagged antibodies (Invitrogen,
Molecular Probes, ThermoFischer Scientific). 0.1% DAPI (Enzo Life
Sciences, Farmingdale, NY) was used to stain the nuclei and sam-
ples were mounted using Fluoromount-G medium (Electron
Microscopy Science, Hatfield, PA) for analysis. Images were taken
with Zeiss LSM510 confocal microscope.
Real Time PCR
Total RNA was extracted from the cells using the Direct-zol RNA
MiniPrep kit (Zymo Research, Irvine, CA). All steps were done
according to the manufacturer’s recommended instructions.
cDNA was reversed transcribed using iScript cDNA synthesis kit
(Bio-Rad, Hercules, CA) as per the manufacturer’s instructions in a
T100 Thermal Cycler (Bio-Rad). The qRT-PCR was performed in
CFX Connect system (BioRad) for various genes (See Supporting
Information Table S2 for primer sequences). Results were normal-
ized to b-actin levels. PCR gel analysis was done by running PCR
products on 1.5% agarose gels (BioExpress, Kaysville, UT) to deter-
mine the presence or absence of PCR products.
RESULTS
Small Molecule-Based Differentiation Protocol
Promotes Eye-Field Induction
Our previous work has shown that retinal differentiation can be
successfully induced in hESCs and iPSCs via inhibition of Wnt and
BMP signaling [3]. Human recombinant proteins DKK1 (Wnt sig-
naling inhibitor) and Noggin (BMP signaling inhibitor), together
with human recombinant IGF1 were used to induce retinal differ-
entiation in our previous protocol, referred as DIN in this study. In
order to establish a more defined and cost-effective protocol for
retinal cell production, we replaced the DKK1 and Noggin with
small molecule inhibitors directed against these pathways and
tested the efficiency of retinal induction between the two proto-
cols. We used a combination of small molecule inhibitors IWR1
(Wnt signaling inhibitor), SB431542 (TGFb signaling inhibitor),
LDN193189 (BMP signaling inhibitor), in addition to human
recombinant protein IGF1. The new retinal induction protocol is
referred as ISLI in this study (Fig. 1A). The NCL1 human iPSC line
was maintained in chemically defined Essential 8 medium (ES8)
(Fig. 1C). Cells were plated for 5–7 days prior to retinal induction.
Cells were treated with either DIN or ISLI containing media for 5
days with daily medium change (Fig. 1A). At 5 days of retinal
induction, a significant decrease in expression of the key pluripo-
tency marker OCT4 was observed in ISLI but not in DIN treated
cells (Fig. 1B). On the other hand, we observed similar increases in
expression of eye-field transcription factors LHX2, PAX6 and RX
under both (DIN and ISLI) culture conditions by qRT-PCR (Fig. 1B).
After 5 days of retinal induction, cells were split into Matrigel
coated 6-well plates and cultured in NSC medium for the rest of
the culture period. At 14 days of retinal induction, qRT-PCR analy-
sis showed a further decrease in expression of OCT4 and similar
expression of eye-field transcription factors LHX2, PAX6, and RX in
both ISLI and DIN treated cells (Fig. 1B). An elevated expression of
RPE-specific transcription factor MITF was also detected in differ-
entiating cells treated with either DIN or ISLI at this stage, indicat-
ing the differentiation of RPE cells in culture (Fig 1B). The above
data shows that the small molecule-based protocol is as efficient
as the recombinant protein protocol in eye-field induction of
human pluripotent stem cells.
Neuro-Retinal and RPE Differentiation of Small
Molecule-Treated iPSCs
Rosette-like retinal clusters formed in cultures at 3 weeks of dif-
ferentiation (Fig. 1D). Those neural clusters were manually
picked up and expanded. By 6 weeks of directed differentiation,
optic-cup like retinal organoids was clearly seen in retinal cell
culture (Fig. 1E). The neural cells were cultured in NSC medium
for extend time period. Upon immunocytochemical (ICC) analy-
sis at 6 weeks of retinal induction, we observed that the cells
expressed retinal stem/progenitor cell marker, LHX2 (87%6 1%
of total DAPI stained cells), and retinal stem cell, ganglion cell,
and amacrine cell marker, PAX6 (71%6 4% of total DAPI stained
cells) (Fig. 2A, 2B). A subset of cells also expressed BRN3, a
marker of differentiated retinal ganglion cells (11%6 1% of total
DAPI stained cells) (Fig. 2C). At this stage, photoreceptor differ-
entiation was often observed in localized clusters. Within those
photoreceptor-enriched areas, 87%6 2% cells expressed pan
photoreceptor marker OTX2 (Fig. 2D), 82%6 4% expressed CRX
(Fig. 2E), and 19%6 1% of total DAPI stained cells expressed
RECOVERIN (Fig. 2F). Upon further differentiation for 12 weeks,
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approximately half the cells in the plate expressed pan markers
of photoreceptors OTX2 (52%6 6% of total DAPI stained cells in
the plate) (Fig. 2G) and RECOVERIN (43%6 3% of total DAPI
stained cells) (Fig. 2H). Cells in culture were also positive for
AIPL1, a marker for mature photoreceptors (50%6 5% of total
DAPI stained cells) (Fig. 2I). Of these, a subpopulation of cells
expressed rod specific markers, NRL (14%6 2%) (Fig. 2J) and
cone specific markers THRB (TRb2, 17%6 2%) (Fig. 2K) and
Cone Arrestin (5%6 1%) (Fig. 2L), indicating the ongoing rod
and cone specification in culture at 12 weeks of directed differ-
entiation. PCR analysis further confirmed the expression of reti-
nal stem/progenitor/inner neuronal cell markers, PAX6, ASCL1,
and LHX2, as well as a set of genes expressed in developing and
differentiated photoreceptors including BLIMP1, RCVRN, NRL,
NEUROD1, THRB(TRB2), and RXRG, in iPSC-derived retinal cells
at 12 weeks of differentiation (Fig. 2M).
Purified RPE cell cultures were also established separately by
manual selection (Fig. 1F). These RPE cells were further cultured
for 8 weeks to promote differentiation and maturation using
methods previously described [24]. At the end of eight weeks, the
cells displayed typical cobblestone morphology and pigmentation
(Fig. 3A). The cells were further analyzed by PCR for various RPE
cell-specific markers. The cells expressed various immature and
mature RPE genes including MITF, BEST1, PMEL17, RPE65, TYR,
ALDH1A3, BMP4, PRNP, RDH5, SIL1, SLC4A2, and TIMP3 (Fig. 3B).
Upon staining, the cultured cells expressed the RPE-specific
transcription factor MITF along with OTX2 (Fig. 3C–3F). The cells
were also stained for two mature RPE-specific markers RPE65
and Bestrophin (Fig. 3G–3J). The above data confirm that the small
molecule based-retinal differentiation protocol leads to genera-
tion of various neuro-retinal and RPE cells in mono-layer cultures
from cGMP-compliant iPSCs.
Figure 1. Small molecule-based differentiation protocol promotes eye-field induction. (A): Schematic diagram showing the timeline of reti-
nal differentiation of human pluripotent cells. DIN represents the human recombinant protein-based protocol; ISLI represented the small-
molecule based differentiation protocol. (B): Quantitative Real-time PCR data comparing gene expression relative to 5-day DIN treatment
showing that the ISLI differentiation protocol worked as efficiently as the previously reported DIN protocol. Downregulation in expression of
pluripotency marker OCT4 and upregulation in expression of early eye-field transcription factors LHX2, PAX6, and RX genes were induced in
differentiating human iPSCs at 5 and 14 days of directed differentiation. Upregulation in expression ofMITF, a RPE specific gene, was detected
at 14 days of directed differentiation with both protocols. (C–F): Representative brightfield images of current Good Manufacturing Practice-
generated undifferentiated human iPSCs (C), neural rosettes in monolayer culture at 3 weeks of differentiation (D), retinal organoid-like clus-
ter in monolayer culture at 6 weeks of differentiation (E), and RPE monolayer culture at 6-weeks (F). Scale bars5 100 mm. Abbreviations:
iPSCs, induced pluripotent stem cells; NSC, neural stem cell; RPE retinal pigment epithelium.
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Figure 2. Neuro-retinal differentiation of small molecule-treated iPSCs. (A–F): Immunocytochemical analysis of retinal differentiation of
human iPSCs in monolayer culture at 6 weeks of small molecule-induced differentiation. The majority of cells (70%–80%) in culture expressed
retinal stem/progenitor marker, LHX2 (A), and retinal stem cell, ganglion cell and amacrine cell marker, PAX6 (71%6 4% of total DAPI stained
cells) (B) at this differentiation stage. In addition, cells expressed markers of retinal ganglion cells, BRN3 (C), pan-photoreceptor markers
OTX2 (D), CRX (E), and RECOVERIN (F). (G–L): At 12 weeks of differentiation, cells in the plate were stained for pan-photoreceptor markers,
OTX2 (G) and RECOVERIN (H) along with other immature photoreceptor marker, AIPL1 (I). Additionally, cells expressed both rod photorecep-
tor specific marker NRL (J) and cone photoreceptor specific marker TRb2 (K) and cone arrestin (L). (M): Quantitative Real-time PCR data
showing the expression of retinal stem cell, ganglion cell, and amacrine cell marker, PAX6, retinal stem cell markers, LHX2 and ASCL1 and a
set of genes expressed in developing and differentiated photoreceptors, BLIMP1, RCVRN, TRB2 (THRB), RHOD, NRL, NEUROD1, BCO, and
RXRc at 12 weeks of retinal induction. Scale bars5 50 mm in (A–L). Abbreviation: iPSCs, induced pluripotent stem cells.
3D Retinal Organoids Derived from iPSCs Following
Low-Attachment Culture
At 4 weeks following retinal induction with ISLI, rosette-like retinal
clusters were manually picked and cultured in low-attachment con-
ditions in NSC medium to allow the formation of self-organized ret-
inal organoids from the iPSC-derived retinal cells (Fig. 4A). IHC
analysis targeted against markers of retinal and photoreceptor pre-
cursor cells was carried out at 6-weeks stage. The retinal organoids
formed laminated structure similar to the retina in vivo. The orga-
noids were predominantly comprised of cells expressing PAX6 (Fig.
4B). There was a polarized distribution of CRX1 and OTX21 cells
in the outer layer of the retinal organoids indicating the differentia-
tion and lamination of photoreceptors at this stage (Fig. 4C, 4E).
Differentiated retinal ganglion cells (BRN31 and ISLET11) and
other inner retinal cell types (amacrine cells, bipolar cells and
horizontal cells) (ISLET1) were present in the inner side of the
retinal organoids (Fig. 4D, 4E). Upon analysis at 12 weeks of dif-
ferentiation, retinal organoids showed clear signs of maturation.
A marked decrease in the number of PAX61 cells was seen
within the organoids (Fig. 4F) and majority of the cells in the
outer layer of the organoids expressed several pan photorecep-
tor markers, OTX2, CRX, BLIMP1, RECOVERIN, and AIPL1 as com-
pared with 6 weeks of differentiation (Fig. 4G–4K). The rod
photoreceptor-specific marker NRL (Fig. 4L) and cone photore-
ceptor specific markers RXRg (Fig. 4M) were also detected in
the photoreceptor layer of the retinal organoid. The laminated
Figure 3. RPE differentiation of small molecule-treated iPSCs. (A): Representative brightfield microscopy image showing RPE cultures exhibit-
ing typical cobblestone morphology and pigmentation at 8 weeks of differentiation. (B): Quantitative Real-time PCR data showing the expres-
sion of various immature and mature RPE genes including BEST1, PMEL17, RPE65, MITF, TYR, ALDH1A3, BMP4, PRNP, RDH5, SIL1, SLC4A2, and
TIMP3 in cells. (C–F): Immunocytochemical analysis showing most of the cells in culture expressed RPE-specific transcription factors OTX2 (C,
D) and MITF (E, F). (G–J): RPE-specific markers RPE65 (G, H) and Bestrophin (I, J) were also expressed in cells at 8 weeks of culture. DAPI (blue)
stains the nuclei of the cells. Scale bars5 20 mm. Abbreviations: iPSCs, induced pluripotent stem cells; RPE retinal pigment epithelium.
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Figure 4. Three-dimensional Retinal organoids derived from induced pluripotent stem cells (iPSCs) via low-attachment culture. (A): Repre-
sentative brightfield microscopy image showing optic cup-like organoids derived from human iPSC in low-attachment culture after 6 weeks of
small molecule-based retinal induction. (B–E): Immunohistochemistry (IHC) analysis showing laminated retinal organoids at 6 weeks where-in
the majority of cells express PAX6, a retinal stem/progenitor cell and inner retinal neuronal marker (B). CRX (C) and OTX2 (E) expressing pho-
toreceptors show a polarized distribution on the apical side of the retinal organoids. BRN3 expressing retinal ganglion cells (D) and ISLET1
positive inner retinal cell types (E) were located in the inner side of the retinal organoids. (F–M): IHC analysis at 12 weeks of differentiation
showing maintenance of retinal lamination with fewer PAX6 positive cells (F). Cells expressing photoreceptor markers, RCVRN (G), OTX2 (H),
CRX (I), BLIMP1 (J), and AIPL1 (K) showed polarized distribution in the apical side of the retinal organoids. Cells in the photoreceptor layer
show both rod photoreceptor specific maker NRL (L) and cone photoreceptor specific marker RXRg (M). DAPI (blue) stains the nuclei of the
cells. Scale bar5 200 mm in (A); Scale bars5 50 mm in (B–M).
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retinal cups also showed clearly defined inner retinal layers com-
prised of BRN31 and ISLET1 retinal ganglion cells and amacrine
cells (Fig. 4G, 4H). The IHC data above on the time course of reti-
nal differentiation and maturation within the organoids is consist-
ent with the time-line of retinal differentiation in 3D retinal
organoid culture previously reported by various groups [6, 25, 26].
It also closely recapitulates retinogenesis during human embryonic
development [27]. Collectively, these data demonstrate that we
are able to generate 3D retinal organoids that resemble develop-
ing human retina from cGMP-compliant iPSCs in culture.
Transplantation of iPSC-Derived Retinal Cells
into Host Mice
Finally, we tested if the iPSC-derived retinal cells generated from
NCL1 line have the ability to integrate into a host retina. Sixty-five
to seventy-day differentiated retinal cells containing young photo-
receptors were transplanted into the host retina. We and others
have shown that young immature photoreceptors integrate maxi-
mally into a host retina [28–30]. To track the cells in host eye fol-
lowing transplantation, the retinal cells were infected with a
replication-incompetent lentivirus expressing eGFP under the
hEF1a ubiquitous promoter which drives expression of GFP by
50%–70% of all cells in the plate as previously described [7]. One
day following infection, media was changed and cells cultured for
an additional 5–7 days prior to transplantation into the subretinal
space of 4–6 weeks old IL2rg–/– mice via trans-corneal subretinal
injection approach. IL2rg–/– mice lack natural killer cells and have
reduced number of mature lymphocytes [31]. These mice thus
serve as a good humanized model for testing integration effi-
ciency. Approximately 500,000 cells in 1 ll volume were trans-
planted into the left eye of each recipient mouse which resulted
in GFP1 donor cells covering approximately one-third of the sub-
retinal space of host eye.We chose to analyze the cell survival and
integration at 8 weeks post transplantation to allow time for maxi-
mal integration of the injected cells in the subretinal space of
IL2rg–/– host eyes [29]. At this time point, we observed human ret-
inal cells integrated into the outer nuclear layer of the host retina
(Fig. 5A-5A0). Recent reports suggest the potential transfer of GFP
protein from the transplanted mouse photoreceptor cells to host
mouse photoreceptors [32–34]. In order to rule out transfer of
GFP from human stem cell-derived photoreceptors, we stained
the transplanted sections with human-specific nuclear antigen
(HuNu) as well as human specific antibody for Lamin B2 nuclear
Figure 5. Integration of human induced pluripotent stem cells (iPSC)-derived retinal cells in IL2rg–/– host retina at 8 weeks following trans-
plantation. (A-A0): Immunohistochemistry analysis showing HuNu1 positive human iPSC-derived retinal cells (red and highlighted with *)
integrated into the photoreceptor layer (ONL) of host IL2rg–/– retina at 8 weeks following transplantation. Integrated HuNu1 human retinal
cells in host ONL express pan-photoreceptor markers, OTX2 (white) and RCVRN (green, white arrows). (B): Integrated GFP1 cells also stained
for human nuclear membrane marker LMNB2 confirming the human origin of those cells. (C-C00): Representative image showing integrated
cell with outer segments projecting toward the RPE layer co-expressing rhodopsin (white arrows). (D-D0,00): Representative image showing
end-feet of integrated human photoreceptors expressing synaptic marker, SV2 (red, white arrows) in the outer plexiform layer of host retina.
(E-E0, F-F0): Representative images showing migrated PAX61 inner retinal neurons co-expressing human LMNB2 marker as well as human
LMNB2 co-expressing GFAP1 cells in the inner retina (marked by arrowheads). DAPI (blue) stains the nuclei of the cells. Abbreviations: GCL,
ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; SP, subretinal space; V, vitreous. Scale bars5 10 mm for (A–F0).
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membrane protein (hLMNB2). Individual integrated cells and cells
present in the subretinal space of host eye were stained for HuNu
(Fig. 5A, 5A0) and hLMNB2 (Fig. 5B) confirming the human origin
of those cells. We found 0.15% (SEM6 0.05%, n5 3) of trans-
planted cell integrated in the host retina based on human-specific
markers. The integrated cells exhibited typical photoreceptor
morphology with properly orientated photoreceptor segments
and had their synaptic end-feet in the outer plexiform layer
(Fig. 5C–5D00,0). The GFP1 cells expressed pan-photoreceptor
markers, OTX2 (Fig. 5A, 5B) and Recoverin (Fig. 5A, 5A0). In addition,
cells also expressed rod photo-transduction protein, Rhodopsin
(Fig. 5C–5C00). We also looked for and detected the expression of
synaptic marker, SV2, in the end-feet of GFP1 cells in the outer
plexiform layer (Fig. 5D–5D00). We occasionally observed PAX61
(Fig. 5E–5E0) and GFAP1 (Fig. 5F–5F0) human cells in the inner ret-
ina suggestive of M€uller glia or astrocyte and ganglion or amacrine
cell migration into host eye. We did not observe any evidence of
tumors formation in the host eye (data not shown). This data shows
that the iPSC-derived retinal cells are able to integrate into host ret-
ina and undergo maturation at 8 weeks following transplantation.
DISCUSSION
Stem cell-based therapies for retinal disease are currently transi-
tioning from preclinical research to phase I/II clinical trials after dec-
ades of studies. A bank of thoroughly validated cGMP-compliant
human iPSC lines is required for moving these therapies to the
clinic. Here, we show that a clinically-compliant human iPSC line
NCL1, made by a standardized cGMP-compliant protocol, can be
efficiently directed to generate neuro-retinal cells including photo-
receptors and RPE cells in vitro. Additionally, we described a refined
small molecule-based retinal induction protocol via inhibition of
Wnt, BMP, and TGFb signaling which minimizes variability we have
previously seen using different lots, manufacturers, and batches of
recombinant proteins. The time course of retinal differentiation in
these human iPSCs with our protocol closely match what has been
reported in previous studies [1, 3, 6, 7, 35]. The small molecule-
based retinal induction protocol used in the study is more defined
and cost effective. Though the components used in the current pro-
tocol to generate retina were not cGMP-grade, cGMP-validated
equivalents are commercially available for most of them. We are
currently looking to outsource the manufacture the small molecules
used in the protocol to generate a cGMP-validated retinal induction
media. We are also testing alternative ECM matrices as Matrigel is
xeno-sourced and efforts are ongoing to optimize the use of alter-
natives including human fibronectin and vitronectin as these would
work best in cGMP setting. One of the critical final steps of any cell
differentiation methodology for in vivo application is to test the
ability of these cells to integrate into host tissue.We confirmed that
the iPSC-derived retinal cells generated using this modified small
molecule (ISLI) protocol behaved similar to our original recombi-
nant protein protocol in terms of their ability to integrate into a
host retina. Transplanted photoreceptors were able to integrate
into host and undergo maturation. The cells expressed rhodopsin in
the outer segment region and synaptic protein SV2 at their end-
feet. This data complements well with our recently published work
showing long-term functional integration of hESC-derived retinal
photoreceptors in Crx mutant mice over 9-months post-transplan-
tation with visual improvements [29].
There has been a significant interest in generating and testing
the applicability of 3D retinal organoids for both transplantation
purposes [36] as well as disease modeling and retinal developmen-
tal studies [37, 38].We tested if the small molecule based protocol
could also generate such organoids. Self-organized laminated optic
cup-like retinal organoids could be efficiently generated by manual
isolation from the cGMP-compliant iPSCs via low-attachment cul-
ture. The retinal organoids recapitulated the key structural features
of developing retina, with photoreceptors (cones and rods) located
in the outermost layer and inner retinal cell types located in the
inner layer of retinal organoids, which is consistent with previously
published studies [6, 21, 25, 26]. The organoids followed a matura-
tion timeline as well with BRN31/ISLET11 ganglion cells appearing
at around 6–8 weeks and more mature photoreceptor markers
such as RECOVERIN and AIPL1 appearing close to 12 weeks of float-
ing culture. These iPSC-derived retinal organoids provide a great in
vitro biological model system for disease modeling as well as devel-
opmental biology studies.
Photoreceptor replacement therapy will be critical for patients
who have lost most of their light sensing cells. However, recent
papers using primary young mouse photoreceptors transplanted
into wild-type hosts have found that majority of GFP1 cells in the
hosts were a result of cytoplasmic protein transfer with minimal
nuclear migration [32–34]. Pearson et al did not see evidence of
nuclear fusion, Singh et al did not find evidence of nuclear migra-
tion based on FISH analysis of X- and Y-chromosomes while Santos-
Ferreira et al did not find any EDU labeled nuclei in the host retina
following transplantation of labeled cells, though they did see rare
Y-chromosome1 integrated cells by FISH. In our report, we observe
cells labeled with two different human-specific nuclear markers,
HuNu and human-specific LMNB2, in all layers of the host retina
suggesting that human-stem cell derived retinal cells have the true
capability to integrate into a host retina. Since these proteins are
part of the nuclear matrix and envelope and previous studies shows
that the transfer is not due to cell fusion, it is unlikely that these
proteins transferred via cytoplasmic or exosome exchange between
host and donor cells. This is consistent with our previous reports
where we reported that integrated hESC-derived photoreceptors in
Crx mutant retinas co-label with human-specific NRL antibody and
HuNu [8]. Our report, however, does not completely exclude cyto-
plasmic transfer as mechanism for some of the GFP1 cells
observed in the host retina. Further studies to better understand
the mechanism for protein transfer and true integration capacity of
cells will be critical prior to their clinical use.
CONCLUSION
Our work validates a directed differentiation strategy using small
molecules to generate retinal cells from cGMP compliant human
iPSCs. These cells in turn have the ability to migrate and integrate
into a host mammalian retina and thus the potential to be used
for cell replacement therapies.
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